MediBeacon

MediBeacon is a medical technology company specializing in the advancement of fluorescent tracer agents and transdermal detection. Our proprietary technology focuses on providing vital and actionable assessment of organ function. The TGFR™ System, including Lumitrace®, is approved for human use by the U.S. FDA and the China NMPA. In addition, the TGFR™ Monitor, TGFR™ Reusable Sensor, and TGFR™ Disposable Ring, have received the EU MDR CE Mark.

The TGFR™ System is a point-of-care exogenous GFR assessment which uses Lumitrace® injection, an inert tracer agent. This non-invasive detection method does not require blood draws, urine sampling, lab analysis, eGFR equations, or patient demographics. It is intended to assess GFR in adults.

Potential technology applications in gastroenterology, ophthalmology, and surgery are in various stages of clinical development. MediBeacon is based in St. Louis, Missouri, with additional operations in Mannheim, Germany.